The effect of CMF adjuvant therapy (cyclophosphamide, methotrexate, and 5-fluorouracil) on endocrine function was investigated in breast cancer patients. CMF therapy resulted in suppression of ovarian function in some premenopausal patients but pituitary function and adrenal function were unaffected. There was an inverse relation between age and duration of treatment required to induce ovarian suppression. Although amenorrhea was achieved within 2-4 months in patients aged 40 years or older, younger women required larger cumulative doses of cytotoxic drugs to induce ovarian dysfunction. Patients younger than 30 years of age continued to menstruate with no major alteration in hormonal levels resulting from the cytotoxic drugs. CMF therapy had no significant effect on hormonal levels in postmenopausal patients indicating that in this group therapeutic response is not mediated via the endocrine system.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/1097-0142(19830301)51:5<803::aid-cncr2820510509>3.0.co;2-v | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Breast Cancer Adjuvant Radiotherapy and Chemotherapy Sequencing: Sequential, Concomitant, or What Else? A Comprehensive Review of the Adjuvant Combinations Journey.
J Clin Med
October 2024
Radiation Oncology Unit, Oncology Research Institute of Basilicata-IRCCS-CROB, 85028 Rionero in Vulture, PZ, Italy.
Article Synopsis
- The treatment sequence for breast cancer has traditionally involved adjuvant chemotherapy followed by adjuvant radiotherapy, but advancements in research have prompted questions about optimizing this order.
- Recent studies have explored various sequencing strategies like sequential, concomitant, and sandwich approaches, evaluating their effectiveness and safety for over 8,000 patients across multiple research studies.
- Despite the extensive analysis, a definitive best practice for the sequencing of adjuvant chemotherapy and radiotherapy remains undetermined, highlighting the need for further investigation in this area.
Chronic Use of Abemaciclib Leading to Breathlessness and Demise: A Case Report.
Cureus
July 2024
Hospital Medicine, Miami Valley Hospital, Dayton, USA.
Checkpoint inhibitor pneumonitis (CIP) is a potentially fatal disease that can occur at any duration of treatment. Patients may present with vague respiratory symptoms such as progressive cough, dyspnea, and decreased activity tolerance. Among checkpoint inhibitors, CIP is higher in programmed death 1 (PD-1) inhibitors.
View Article and Find Full Text PDFAccelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.
Lancet Oncol
December 2023
University of Edinburgh Cancer Centre, Institute of Genetics and Cancer, Western General Hospital, Edinburgh, UK.
Background: Adjuvant chemotherapy for patients with early breast cancer improves outcomes but its toxicity affects patients' quality of life (QOL). The UK TACT2 trial investigated whether accelerated epirubicin improves time to recurrence and if oral capecitabine is non-inferior to cyclophosphamide, methotrexate, and fluorouracil (CMF) for efficacy with less toxicity. Results showed no benefit for accelerated epirubicin and capecitabine was non-inferior.
View Article and Find Full Text PDFDistribution of PD-L1, TROP2 and HER2- "lowness" in early triple-negative breast cancer: an opportunity for treatment de-escalation.
Clin Transl Oncol
May 2024
Breast Cancer Clinical Research Unit, CNIO Spanish National Cancer Research Center, Melchor Fernandez Almagro 3, 28029, Madrid, Spain.
Background: HER2, TROP2 and PD-L1 are novel targets in triple-negative breast cancer (TNBC). The combined expression status of these targets, and whether they can define prognostic subgroups, is currently undefined.
Methods: Immunohistochemistry was used to determine HER2, TROP2 and PD-L1 levels in 459 TNBC cases, that received in the adjuvant/neoadjuvant setting active surveillance, CMF, anthracycline-, anthracycline plus taxane-, or carboplatin-containing regimes.
Impact of Chemotherapy Regimens on Body Composition of Breast Cancer Women: A Multicenter Study across Four Brazilian Regions.
Nutrients
March 2023
Csentro Avançado de Diagnóstico da Mama, Clinics Hospital, Federal University of Goias, Goiania 74175-120, Brazil.
This study aimed to investigate the effect of chemotherapy (CT) and its different types of regimens on the anthropometry and body composition of women with breast cancer. Three-hundred-and-four women with breast cancer were enrolled in this multicenter study. The participants were evaluated before the infusion of the first cycle of CT (pre-CT), and until two weeks after CT completion (post-CT), regarding body weight, body mass index (BMI); waist circumference (WC); waist-to-height ratio (WHtR); conicity index (C-index); fat mass index (FMI); and fat-free mass index (FFMI).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!